<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04520646</url>
  </required_header>
  <id_info>
    <org_study_id>KY2020-849</org_study_id>
    <nct_id>NCT04520646</nct_id>
  </id_info>
  <brief_title>A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy</brief_title>
  <official_title>A Pilot Study of Empagliflozin in the Treatment of Acromegalic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Huashan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Huashan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acromegaly is a disease characterized by excess growth hormone(GH) and insulin like growth&#xD;
      factor(IGF)-1. Pituitary GH secreting adenoma is the major cause of acromegaly. Acromegalic&#xD;
      cardiomyopathy is one of the leading causes of death in acromegalic patients. No efficient&#xD;
      medicine is available for acromegalic cardiomyopathy until now and there were limited&#xD;
      studies. Empagliflozin is proved to decrease the risk of heart failure in diabetic patients&#xD;
      and independent of blood glucose control. We planed to evaluate the structure of heart by MRI&#xD;
      before and after 6 months treatment with empagliflozin in acromegalic patients to investigate&#xD;
      the effect of empagliflozin on acromegalic cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular mass index</measure>
    <time_frame>6 months</time_frame>
    <description>the changes in left ventricular mass index by heart MRI</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Acromegaly</condition>
  <condition>Cardiomyopathies</condition>
  <arm_group>
    <arm_group_label>empagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>empagliflozin is added on the basis of the original treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empagliflozin</intervention_name>
    <description>empagliflozin of 10mg/day is added on the basis of primary care</description>
    <arm_group_label>empagliflozin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients with pituitary GH adenomas confirmed by surgery&#xD;
&#xD;
        active acromegalic patients although treated with surgery,radiation therapy and&#xD;
        somatostatin analogs&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with contraindications to empagliflozin pregnant patients patients with poor&#xD;
             control of hypertension(SBP&gt;150mmHg or DBP&gt;95mmHg patients with contraindications to&#xD;
             MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cuiyun Wu</last_name>
    <phone>+86(21)52888045</phone>
    <email>mhe2004@263.net</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huashan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min He, Doctor</last_name>
      <phone>+862152887027</phone>
      <email>mhe2004@263.net</email>
    </contact>
    <investigator>
      <last_name>Zhaoyun Zhang, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Huashan Hospital</investigator_affiliation>
    <investigator_full_name>Zhaoyun Zhang</investigator_full_name>
    <investigator_title>vice director of endocrine department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Empagliflozin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

